A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201.
Iqbal S, McDonough S, Lenz H, Ilson D, Burtness B, Nangia C, Barzi A, Schneider C, Liu J, Dotan E, Guthrie K, Hochster H. A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. Journal Of Clinical Oncology 2017, 35: 4009-4009. DOI: 10.1200/jco.2017.35.15_suppl.4009.Peer-Reviewed Original ResearchAdvanced esophagogastric cancerERCC1 levelsRandomized phase II pilot studyRandomized phase II studyPhase II pilot studyHigh ERCC1 levelsPhase II studyHER2-negative patientsGastroesophageal junction cancerDifferential treatment effectsMetastatic esophagealEsophagogastric cancerII studyJunction cancerNegative patientsPS 0Superior PFSERCC1 expressionTx groupFOLFOXPlatinum sensitivityRetrospective dataPFSHigh subgroupPilot study